 | |
| Clinical data | |
|---|---|
| Trade names | Photofrin |
| AHFS/Drugs.com | Consumer Drug Information |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | ~90% |
| Eliminationhalf-life | 21.5 days (mean) |
| Excretion | Fecal |
| Identifiers | |
| CAS Number |
|
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C68H74N8O11 (for n=0) |
| Molar mass | 1179.36 g/mol (for n=0) g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Porfimer sodium, sold asPhotofrin, is aphotosensitizer used inphotodynamic therapy andradiation therapy and forpalliative treatment of obstructing endobronchialnon-small cell lung carcinoma and obstructingesophageal cancer.
Porfimer is a mixture ofoligomers formed by ether and ester linkages of up to eightporphyrin units.[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.[2]
Porfimer isHaematoporphyrin Derivative (HpD) (SeePDT).
It was approved in Canada in 1993 for the treatment ofbladder cancer.[2]It was approved in Japan in 1994 (for early stage lung cancer?).[2]It was approved by theU.S. FDA in December 1995 foresophageal cancer, and in 1998, it was approved for the treatment of earlynon-small cell lung cancer.[2]
In August 2003 the FDA approved its use forBarrett's esophagus.[3]